663 results on '"Groettrup, Marcus"'
Search Results
2. PLGA particle vaccination elicits resident memory CD8 T cells protecting from tumors and infection
3. Parkin is an E3 ligase for the ubiquitin-like modifier FAT10, which inhibits Parkin activation and mitophagy
4. The ubiquitin-like modifier FAT10 inhibits retinal PDE6 activity and mediates its proteasomal degradation
5. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
6. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
7. The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10
8. The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells
9. The ubiquitin-like modifier FAT10 stimulates the activity of deubiquitylating enzyme OTUB1
10. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors
11. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
12. On the role of the immunoproteasome in transplant rejection
13. Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma
14. No prolongation of skin allograft survival by immunoproteasome inhibition in mice
15. Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-κB activation
16. An Inhibitor of HIV-1 Protease Modulates Proteasome Activity, Antigen Presentation, and T Cell Responses
17. The expression profile of the ubiquitin-like modifier FAT10 in immune cells suggests cell type-specific functions
18. The Subunits MECL-1 and LMP2 are Mutually Required for Incorporation into the 20S Proteasome
19. The ubiquitin-like modifier FAT10 in cancer development
20. FAT10 : Activated by UBA6 and Functioning in Protein Degradation
21. Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation
22. Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10
23. Testing the Impact of Protease Inhibitors in Antigen Presentation Assays
24. The ubiquitin-like modifier FAT10 interferes with SUMO activation
25. The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense
26. Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease
27. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
28. Subunit specific inhibitors of proteasomes and their potential for immunomodulation
29. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis
30. The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: Evidence from a randomized controlled trial
31. The unique functions of tissue-specific proteasomes
32. FAT10ylation as a signal for proteasomal degradation
33. Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
34. Author Correction: The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation
35. The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation
36. Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation
37. Endosomal trafficking of open Major Histocompatibility Class I conformers—Implications for presentation of endocytosed antigens
38. Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit
39. Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins
40. The immunoproteasome in antigen processing and other immunological functions
41. Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome
42. The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells
43. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice
44. An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma
45. Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
46. Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome
47. Immunoproteasome Inhibition Reduces the T Helper 2 Response in Mouse Models of Allergic Airway Inflammation
48. Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress
49. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy
50. A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.